PROTEKT years 1-3 (1999-2002): study design and methodology.
Harding
I
I
The Micron Group, Marmont Priory Farm, Upwell, Wisbech, Cambridgeshire PE14 9AR, UK. ian.harding@micron-research.com
Felmingham
D
D
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D007391:International Cooperation; D048628:Ketolides / Q000494:pharmacology*; D008137:Longitudinal Studies; D018942:Macrolides / Q000494:pharmacology*; D008297:Male; D008722:Methods; D008826:Microbial Sensitivity Tests; D012107:Research Design; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D006113:United Kingdom
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin